Previous Close | 14.45 |
Open | 16.70 |
Bid | 10.25 |
Ask | 12.25 |
Strike | 85.00 |
Expire Date | 2025-01-17 |
Day's Range | 16.60 - 16.70 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.